|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
gptkb:physicist
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
|
|
gptkbp:average_temperature
|
2 to 8 ° C
|
|
gptkbp:brand
|
gptkb:Saxenda
gptkb:Victoza
|
|
gptkbp:class
|
antidiabetic agent
antiobesity agent
|
|
gptkbp:clinical_trial
|
gptkb:unknown
weight loss
Phase 3
blood sugar control
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
gptkb:medullary_thyroid_carcinoma
|
|
gptkbp:developed_by
|
gptkb:Novo_Nordisk
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
injectable solution
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
liraglutide
|
|
gptkbp:indication
|
glycemic control
chronic weight management
|
|
gptkbp:ingredients
|
gptkb:liraglutide
C172 H265 N43 O51
|
|
gptkbp:interacts_with
|
gptkb:Company
sulfonylureas
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_used_for
|
obesity
type 2 diabetes
|
|
gptkbp:lifespan
|
13 hours
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:metabolism
|
proteolytic cleavage
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:provides_information_on
|
gptkb:healthcare_organization
gptkb:European_Association_for_the_Study_of_Diabetes
|
|
gptkbp:research_focus
|
combination therapies
long-term efficacy
safety in special populations
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
vomiting
diarrhea
constipation
hypoglycemia
pancreatitis
gallbladder disease
kidney injury
|
|
gptkbp:traded_on
|
gptkb:Saxenda
gptkb:Victoza
|
|
gptkbp:weight
|
3751.4 g/mol
|
|
gptkbp:bfsParent
|
gptkb:GLP-1_receptor
|
|
gptkbp:bfsLayer
|
5
|